ARTICLE | Emerging Company Profile
With Apertura, Deerfield takes fine-tuning approach to gene therapy
The NYC-based company is using its $67 million series A round to develop gene therapies incorporating engineered AAVs and gene regulatory elements
May 5, 2022 11:30 PM UTC
By combining platforms from a pair of labs at the Broad and Harvard, Deerfield-built Apertura is fine-tuning the delivery and expression of AAV gene therapies to control the location and strength of their activity.
Apertura Gene Therapy LLC’s $67 million series A round is the latest gene therapy investment disclosed by Deerfield Management Company. Past deals include venture investments in Spark Therapeutics Inc. and AveXis Inc., acquired by Roche (SIX:ROG; OTCQX:RHHBY) and Novartis AG (SIX:NOVN; NYSE:NVS), respectively, as well as more recent investments in Jaguar Gene Therapy LLC and The Center for Breakthrough Medicines, a cell and gene therapy-focused CDMO...